Core Viewpoint - Ferguson Enterprises Inc. is conducting its Q3 2025 earnings conference call, indicating a focus on financial performance and future outlook [1][2][3]. Group 1: Company Overview - The conference call is led by Brian C. Lantz, Vice President of Investor Relations and Communications, who welcomes participants and introduces the session [2][3]. - The earnings announcement for Q3 2025 has been made available on the company's corporate website and SEC filings page, highlighting transparency in financial reporting [3]. Group 2: Forward-Looking Statements - The company reminds participants that some statements made during the call may be forward-looking and subject to risks and uncertainties that could lead to actual results differing from projections [4]. - The company disclaims any obligation to update forward-looking statements, emphasizing the importance of the current date in relation to expectations [4].

Group 1 - The conference call is for Kohl's Corporation's First Quarter 2025 earnings, indicating a focus on financial performance and future initiatives [1] - Trevor Novotny, Senior Manager of Investor Relations, is leading the call, suggesting a structured approach to investor communication [1] - The call includes a question-and-answer session, highlighting engagement with analysts and investors [1] Group 2 - Forward-looking statements regarding projected financial results and future initiatives are made, which are subject to risks and uncertainties [2] - The company emphasizes that actual results may differ materially from projections due to various risks outlined in their annual report [2] - Non-GAAP financial measures may be referenced during the call, indicating a focus on alternative financial metrics for analysis [3]

VNET Group, Inc. (NASDAQ:VNET) Q1 2025 - Earnings Conference Call May 28, 2025 8:00 AM ET Company Participants Xinyuan Liu - Director of Investor Relations Ju Ma - Rotating President and General Manager of the AIDC Strategic Business Group Qiyu Wang - Chief Financial Officer Conference Call Participants Tom Tang - Morgan Stanley Edison Lee - Jefferies Daley Li - Bank of America Securities Louis Tseng - Citi Sarah Wong - UBS Operator Hello, ladies and gentlemen. Thank you for standing by for the First Quarte ...

Corporacion America Airports S.A. (NYSE:CAAP) Q1 2025 Earnings Conference Call May 23, 2025 10:00 AM ET Company Participants Patricio Inaki Esnaola - Head of Investor Relations Martin Eurnekian - Chief Executive Officer Jorge Arruda - Chief Financial Officer Conference Call Participants Fernanda Recchia - BTIG Alejandro Demichelis - Jefferies Stephen Trent - Citi Operator Good morning, and welcome to the Corporacion America Airports First Quarter 2025 Conference Call. A slide presentation accompanies today' ...

Core Insights - The company reported a relatively flat global insurance volume year-over-year, with a nominal decline of 0.3% in unit sales globally and 0.9% in the United States [5]. Group 1: Insurance Business Performance - Global insurance unit sales grew by 1.3% when accounting for the extra business day in leap year 2024, while U.S. insurance units sold increased by 0.6% [5]. - Total loss frequency continues to rise, indicating potential challenges in the insurance sector [5]. Group 2: Financial Performance Overview - The CEO, Jeff Liaw, highlighted the preparation for the 2025 catastrophe season, indicating proactive measures being taken by the company [4].

Core Viewpoint - Gossamer Bio, Inc. reported its Q1 2025 financial results and provided a corporate update during the earnings call, highlighting key developments and future outlooks for the company [3]. Financial Results - The earnings call was initiated by Bryan Giraudo, the Chief Financial Officer and Chief Operating Officer, who presented the financial results for the first quarter of 2025 [2][3]. - Gossamer Bio issued a press release earlier in the day detailing its financial performance and corporate updates [3]. Management Team - The call featured key members of the management team, including Faheem Hasnain (Founder, Chairman, and CEO), Dr. Richard Aranda (Chief Medical Officer), Caryn Peterson (EVP, Regulatory Affairs), and Bob Smith (Chief Commercial Officer) [3]. Forward-Looking Statements - The management cautioned that the call would include forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from those projected [4][5].

Group 1 - The conference call is focused on Fluent's First Quarter 2025 Earnings Results, featuring comments from CEO Don Patrick and CFO Ryan Perfit [1] - The call is being webcast live and will be available for replay on Fluent's website [2] - Management will discuss forward-looking statements that may involve risks and uncertainties related to the company's business [3][4] Group 2 - Certain non-GAAP financial information will be presented during the call [5]

Group 1 - Omeros Corporation held its Q1 2025 earnings conference call on May 15, 2025, at 4:30 PM ET [1] - The call included participants from the company such as the Chairman & CEO, Chief Accounting Officer, and Chief Commercial Officer [1][6] - The call was recorded and a replay will be available on the company's website for one week [1] Group 2 - Jennifer Williams, representing Investor Relations, opened the call and thanked participants for joining [2][3] - Forward-looking statements were mentioned, indicating that they are based on management's beliefs and expectations and are subject to change [4] - The call was turned over to Dr. Gregory Demopulos, the Chairman and CEO, who was joined by other key executives [5][6]

Financial Data and Key Metrics Changes - Zometica reported total revenue of $6.5 million for Q1 2025, reflecting a 4% increase year-over-year, marking the seventeenth consecutive quarter of record revenue growth [5][14] - Gross margin improved to 68%, up from 66% in Q1 2024 [15] - The net loss for the quarter was $63.8 million, significantly higher than the net loss of $9.2 million in the prior year, primarily due to a $55.8 million non-cash impairment expense [16][17] Business Line Data and Key Metrics Changes - Revenue from the Therapeutic Devices segment was $5.9 million, while the Diagnostics segment generated approximately $600,000, a decrease of 25% [15] - Consumables revenue reached $4.5 million, a 13% increase year-over-year, representing about 70% of total revenue [14][15] - The TruForma platform saw a 41% year-over-year growth, driven by the launch of new assays [8] Market Data and Key Metrics Changes - International revenue grew approximately 32% year-over-year, indicating strong performance in new international markets [8] - The equine market expansion is a key focus, with new product launches aimed at increasing adoption and utilization [6][19] Company Strategy and Development Direction - The company aims to achieve cash flow breakeven and GAAP profitability through operational efficiencies and cost reductions [11][20] - Key growth strategies include expanding into the equine market, international market growth, and enhancing the TruForma platform with new assays [19][20] - Zometica is also focusing on optimizing its infrastructure to support growth and reduce costs [11][21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential in 2025, particularly in the equine market and international expansion [18][19] - The company is committed to reducing cash operating expenses and improving overall cost structure [12][21] - Management highlighted the importance of achieving cash flow profitability to support stock price appreciation [50][51] Other Important Information - The company relocated its headquarters to a smaller facility, which is expected to reduce overhead costs by over $200,000 annually [11] - Zometica has no debt and ended the quarter with $64.6 million in cash and cash equivalents [17][24] Q&A Session All Questions and Answers Question: Why have management options not been repriced or new options issued, instead of salary? - Management believes it is inappropriate to change the strike price of options and continues to issue option grants to employees [27] Question: Why are marketing costs much higher than the industry averages? - Marketing costs are high due to the nature of introducing new products to the market, which requires significant investment [28][30] Question: Are you looking to expand into retail vet stores? - Currently, the company sells one product line through online channels and has limited presence in brick-and-mortar stores [31] Question: Is there a strategy for getting institutional coverage, investment banking relations, and so on? - Institutional coverage is challenging due to the stock price being below a dollar, and the company is not prioritizing this at the moment [35] Question: Are you using or planning on using AI to expand the number and rate of discovery of new assays for TruForma? - The company is not currently using AI for this purpose but has a good cadence of assays under consideration for development [39] Question: How profitable has the new Vetigel product been? - The Vetigel product has favorable margins, and the company is focused on acquiring consumable product lines that can leverage the existing client base [41][42] Question: Why are you focusing so heavily on equine when it's only 5% the size of the domestic animal market? - The equine market has high penetration and demand for the company's products, justifying the focus [43] Question: What is the status of TruView? - The TruView platform is nearing completion for AI reporting and is expected to launch soon [45] Question: Do you plan on hiring a new CFO to replace Scott? - The current Vice President of Finance is doing a good job, and hiring a new CFO is not a priority at this time [46] Question: Are there any plans in place to try and increase the stock share price? - The company is focusing on internal growth and operational improvements to drive stock price appreciation [48][50] Question: What is the status of the cancer assay? - The cancer assay concept has been abandoned as it was determined not to be viable [58] Question: Have the tariffs affected the international expansion at all? - Tariffs have had a minor impact, but the company expects to continue expanding its international market presence [60][62]

Core Viewpoint - Ondas Holdings Inc. is conducting its Q1 2025 earnings conference call, indicating a focus on financial performance and strategic direction for the upcoming quarter [1]. Company Participants - The call features key executives including Eric Brock (Chairman, President, and CEO), Neil Laird (Interim CFO), Oshri Lugassy (Co-CEO, Autonomous Systems), and Markus Nottelmann (CEO, Ondas Networks) [1]. Conference Call Structure - The conference call is structured to allow participants to listen only, with an emphasis on forward-looking statements that may contain risks and uncertainties [2]. - The company has provided a reconciliation of non-GAAP financial measures to GAAP measures, highlighting the importance of these metrics for understanding business trends [3].